AlphaCore Pharma Initiates ACP-501 (rhLCAT) Clinical Trial in Patients With Coronary Artery Disease
3/30/2012 11:06:47 AM
ANN ARBOR, Mich.--(BUSINESS WIRE)--AlphaCore Pharma, a biopharmaceutical company developing ACP-501 (rhLCAT) for the treatment of high risk atherosclerosis and serious lipid metabolism disorders, today announced the initiation of a Phase 1 study of ACP-501 in patients with stable coronary arterial disease. The study is designed to assess the safety, tolerability, pharmacokinetics and lipid effects of ACP-501. The trial will be conducted by the National Institute of Health (NIH) and Robert D. Shamburek, MD, will serve as the principal investigator of the study.
comments powered by